• New Techniques Make RNA Accessible to Study Variants of Uncertain Significance

    Oct 03 | Bio-IT World | New work from Dr. Lachlan Jolly and the University of Adelaide’s Neurobiology Research Group is using cutting-edge RNA-based techniques to resolve genetic variants of uncertain significance (VUS) that can't be diagnosed through traditional methods. Many disease-causing genes do not express RNA in accessible tissues like blood or skin, leaving many patients without a clear diagnosis. To overcome this, the team is utilizing two innovative methods—transactivation and transdifferentiation. More

  • Fresh Hope of a Functional Cure for HIV

    Oct 02 | Bio-IT World | The longstanding reality for most individuals infected with human immunodeficiency virus (HIV) is a lifetime of taking antiretroviral therapy (ART). But the creation of an HIV-like virus particle that both reduces viral reservoirs and boosts the immune system could make it possible for at least half of all patients to achieve long-term control of the virus after a brief stint of treatment. More

  • New Alzheimer’s Approach Suggested by Data Mining

    Oct 01 | Bio-IT World | In a paper published last month in Brain, researchers explored data from 24 past Alzheimer’s Disease trials and posited a new theory for why the most recent drugs have shown some success against the disease, and senior author Alberto Espay issued an open data challenge for pharma companies working in the space. More

  • Follow the Money: T Cell Engineering, Kidney Transplants, Intravascular Imaging Technology, More

    Sep 26 | Bio-IT World | ArsenalBio plans to advance their lead programs through development invests in candidates for solid tumor cancers based on its proprietary T cell engineering technology; eGenesis moves to a first-in-human study for kidney transplant; SpectraWAVE will advance commercial expansion and product additions to their 510k-cleared HyperVue Imaging System; and more. More

  • Illumina Reacts to GRAIL Acquisition Ruling, AstraZeneca, Moffitt Cancer Center Partnership, 10x Genomics Platforms Mentioned, More

    Sep 25 | Bio-IT World | Illumina welcomed the European Court of Justice's judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL; Moffitt Cancer Center announced a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies; 10x Genomics’ Chromium Single Cell Gene Expression and Xenium In Situ platforms in publication; and more. More

  • A Pill That Triggers a Desire to Exercise? Maybe... For Now, Just Go to the Gym

    Sep 24 | Bio-IT World | What Wegovy has done for people who want to lose weight but dislike the work involved might one day find its match with a pill that pumps up a person’s desire to exercise—all by adjusting their level of interleukin 15 (IL-15), a cytokine that in the brain stimulates locomotor activity. At least that’s one of the promising possibilities dredged up by a study in mice finding a muscle-brain pathway controlling “eagerness to train more when we exercise." More

  • The Rise and Importance of Population-Scale Genome Programs

    Sep 20 | Bio-IT World | With the wealth of population-scale projects going on, we have entered a golden age of genomics. Based on efforts such as the All of Us program in the U.S. and the UK Biobank, among many others, we are poised to discover more than we ever knew about natural genetic diversity, what’s considered “normal” human biology, and the continuum of health and disease. More

  • 2025 Bio-IT World Innovative Practices Awards Call for Entries

    Sep 18 | Bio-IT World | Bio-IT World is accepting entries for the 2025 Innovative Practices Awards, a competition designed to recognize the most exciting partnerships and projects pushing the life sciences industry forward. More

  • NVIDIA Bundles NIMs for GenAI Drug Target Screening

    Sep 17 | Bio-IT World | Last June, NVIDIA launched NIM—NVIDIA Inference Microservices—a simple, standardized way to add generative AI to applications. Now the company has released the NIM Agent Blueprint for generative AI-based virtual screening. In a blog post announcing the news, NVIDIA describes a NIM Agent Blueprint as integrated NIMs that build a workflow. More

  • ‘Dancing Molecules’ Could Be the Key to Cartilage Regeneration

    Sep 12 | Bio-IT World | Osteoarthritis affects more than 528 million people around the world. Cartilage in joints wears down, and bones rub against each other, causing pain, stiffness, and mobility issues. Current treatments slow down cartilage degeneration, though patients inevitably need expensive joint replacement surgery. However, researchers at Northwestern University discovered “dancing molecules” that might be the key to the first cartilage regenerative therapy. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!